Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

Price CF, Tyssen D, Sonza S, Davie A, Evans S, Lewis GR, Xia S, Spelman T, Hodsman P, Moench TR, Humberstone A, Paull JR, Tachedjian G.

PLoS One. 2011;6(9):e24095. doi: 10.1371/journal.pone.0024095. Epub 2011 Sep 15.

PMID:
21935377
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Structure activity relationship of dendrimer microbicides with dual action antiviral activity.

Tyssen D, Henderson SA, Johnson A, Sterjovski J, Moore K, La J, Zanin M, Sonza S, Karellas P, Giannis MP, Krippner G, Wesselingh S, McCarthy T, Gorry PR, Ramsland PA, Cone R, Paull JR, Lewis GR, Tachedjian G.

PLoS One. 2010 Aug 23;5(8):e12309. doi: 10.1371/journal.pone.0012309.

PMID:
20808791
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).

McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C, Jacobson C; MTN-004 Protocol Team.

AIDS. 2011 May 15;25(8):1057-64. doi: 10.1097/QAD.0b013e328346bd3e.

PMID:
21505316
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection.

Rupp R, Rosenthal SL, Stanberry LR.

Int J Nanomedicine. 2007;2(4):561-6. Review.

PMID:
18203424
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses.

Gong E, Matthews B, McCarthy T, Chu J, Holan G, Raff J, Sacks S.

Antiviral Res. 2005 Dec;68(3):139-46. Epub 2005 Sep 27.

PMID:
16219368
[PubMed - indexed for MEDLINE]
6.

A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.

Cohen CR, Brown J, Moscicki AB, Bukusi EA, Paull JR, Price CF, Shiboski S.

PLoS One. 2011 Jan 20;6(1):e16258. doi: 10.1371/journal.pone.0016258.

PMID:
21311578
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.

O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR.

Sex Transm Dis. 2010 Feb;37(2):100-4. doi: 10.1097/OLQ.0b013e3181bc0aac.

PMID:
19823111
[PubMed - indexed for MEDLINE]
8.

Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.

Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, Aldunate M, Gorry PR, Ramsland PA, Lewis GR, Paull JR, Sonza S, Tachedjian G.

Antiviral Res. 2011 Jun;90(3):195-9. doi: 10.1016/j.antiviral.2011.03.186. Epub 2011 Apr 1.

PMID:
21459115
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model.

Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL.

Antimicrob Agents Chemother. 2006 May;50(5):1696-700.

PMID:
16641437
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action.

Mumper RJ, Bell MA, Worthen DR, Cone RA, Lewis GR, Paull JR, Moench TR.

Drug Dev Ind Pharm. 2009 May;35(5):515-24. doi: 10.1080/03639040802488097.

PMID:
19040181
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, Madan RP, Cohen HW, Petrie J, Ford T, Soto-Torres L, Profy AT, Herold BC.

PLoS One. 2010 Jan 22;5(1):e8781. doi: 10.1371/journal.pone.0008781.

PMID:
20107502
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis.

Chen MY, Millwood IY, Wand H, Poynten M, Law M, Kaldor JM, Wesselingh S, Price CF, Clark LJ, Paull JR, Fairley CK.

J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):375-80. doi: 10.1097/QAI.0b013e318198a7e6.

PMID:
19214122
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.

Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC.

J Infect Dis. 2006 Jan 1;193(1):27-35. Epub 2005 Nov 17.

PMID:
16323128
[PubMed - indexed for MEDLINE]
Free Article
14.

UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.

Haaland RE, Evans-Strickfaden T, Holder A, Pau CP, McNicholl JM, Chaikummao S, Chonwattana W, Hart CE.

Antimicrob Agents Chemother. 2012 Jul;56(7):3592-6. doi: 10.1128/AAC.00452-12. Epub 2012 Apr 16.

PMID:
22508307
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques.

Jiang YH, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, Tsai CC.

AIDS Res Hum Retroviruses. 2005 Mar;21(3):207-13.

PMID:
15795526
[PubMed - indexed for MEDLINE]
16.

Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge.

Fernández-Romero JA, Abraham CJ, Rodriguez A, Kizima L, Jean-Pierre N, Menon R, Begay O, Seidor S, Ford BE, Gil PI, Peters J, Katz D, Robbiani M, Zydowsky TM.

Antimicrob Agents Chemother. 2012 Jan;56(1):358-68. doi: 10.1128/AAC.05461-11. Epub 2011 Nov 7.

PMID:
22064530
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women.

Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, Romano J.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1181-90. doi: 10.1089/aid.2009.0227. Epub 2010 Sep 21.

PMID:
20854207
[PubMed - indexed for MEDLINE]
18.

Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.

Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A.

Lancet. 2012 Feb 18;379(9816):641-7. doi: 10.1016/S0140-6736(11)61750-9. Epub 2012 Jan 4. Erratum in: Lancet. 2012 Feb 18;379(9816):616.

PMID:
22225814
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission.

Yang J, Li L, Jin H, Tan S, Qiu J, Yang L, Ding Y, Jiang ZH, Jiang S, Liu S.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1498-508. doi: 10.1089/AID.2012.0084. Epub 2012 Sep 11.

PMID:
22867271
[PubMed - indexed for MEDLINE]
20.

A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.

Van Damme L, Wright A, Depraetere K, Rosenstein I, Vandersmissen V, Poulter L, McKinlay M, Van Dyck E, Weber J, Profy A, Laga M, Kitchen V.

Sex Transm Infect. 2000 Apr;76(2):126-30.

PMID:
10858715
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk